Pharmaceutical giant GSK is planning to research whether, as a scientific paper published earlier this week suggests, its meningitis B vaccine offers some protection against gonorrhea.

What form the work will take and how quickly it will happen isn’t yet clear; it’s still early days, a buoyant Rino Rappuoli, chief scientist for GSK Vaccines, told STAT in an interview.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Any gonorrhea vaccine will not be 100% reliable. Better to give yourself 1.2 million units of Procaine Penicillin G in each thigh before you go out with a new date. Will also cover you for syphillis.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy